Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study, co-lead by Dr Felipe Galvez-Cancino from the Centre for Immuno-Oncology, has shown that Treg cell depletion can suppress tumour growth in one of the deadliest types of cancer.

Researcher working at a lab

A glioblastoma is a fast-growing type of brain tumour and the most common malignant brain tumour in adults. It’s considered to be one of the deadliest types of cancer as it responds poorly to immunotherapy.

Dr Felipe Galvez-Cancino, Kidani Fellow and Group Leader at NDM’s Centre for Immuno-Oncology, co-lead a study on the impact of regulatory T cell (Treg) depletion on the progression of glioblastoma and immunotherapy responsiveness. 

The research found that Treg depletion suppressed tumour growth in preclinical models and in human tissues. In order to mediate Treg depletion, depleting antibodies are dependent on tumour-infiltrating macrophages that are specialised in antibody-dependent cellular phagocytosis. This means that after administering depleting antibodies to mice with glioblastomas, specific macrophages mediated the elimination of the target regulatory CD4+ T cells.

 

Find out more on the Nuffield Department of Medicine website.

 

 

 

Similar stories

Alan Davidson Foundation renews funding for ground-breaking motor neuron disease research at Oxford

As part of its renewed commitment, the Alan Davidson Foundation will continue to fund a full-time project manager to facilitate the ongoing coordination and growth of the ACORN study. The foundation is also contributing to the cost of a research fellow to support the next phase of the project.